Clinical Trial Update: Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 68Gallium-DOTATATE PET/CT for detecting neuroendocrine tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hippel-lindau Disease
• Neuroendocrine Tumors
• Von Hippel-lindau Syndrome

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neuroendocrine Tumors, Von Hippel-Lindau Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2019-04-02